Translational Session

Major Clinical Trials for Diabetic Kidney Disease: CREDENCE and SONAR

November 08, 2019 | 10:30 AM - 12:30 PM

Location: Hall D, Walter E. Washington Convention Center

Session Description

The CREDENCE clinical trial of an SGLT-2 inhibitor, canagliflozin, was stopped early for evidence of efficacy in patients with type 2 diabetes and diabetic kidney disease (DKD). SONAR is a clinical trial that tested the effect of an endothelin A receptor antagonist, atrasentan, for DKD with a unique enrichment design. This session presents the key elements of these landmark trials, which are expected to set a new course in motion for DKD.

Learning Objective(s)

  • Discuss the rationale and background for CREDENCE and SONAR
  • Describe new learnings from these pivotal clinical trials

Learning Pathway(s)

  • Diabetes and Metabolism

Moderators

  • Peter Rossing, MD
  • Katherine R. Tuttle, MD, FASN

Presentations

  • CREDENCE Background, Study Design, and Conduct
    10:30 AM - 10:55 AM
    Carol A. Pollock, MD, PhD
  • CREDENCE Primary Outcomes and Other Major Outcomes
    10:55 AM - 11:20 AM
    Vlado Perkovic, MBBS, PhD, FASN
  • SONAR Background, Study Design, and Conduct
    11:20 AM - 11:45 AM
    Hiddo Jan Lambers Heerspink, PhD
  • SONAR Primary Outcomes and Other Major Outcomes
    11:45 AM - 12:10 PM
    Dick de Zeeuw, MD, PhD
  • Panel and Audience Discussion
    12:10 PM - 12:30 PM